tbuckley/cabot-search huggingface dataset:
The acceptability of cognitive analytic therapy (CAT): Meta-analysis and benchmarking of treatment refusal and treatment dropout rates
Authors: Melanie Simmonds-Buckley, Ese-Oghene Osivwemu, Stephen Kellett, Catherine Taylor
Journal: Clinical Psychology Review (2022)

To estimate treatment refusal and treatment dropout rates for cognitive analytic therapy (CAT) and then benchmark these rates against other psychotherapies. PROSPERO registration CRD4202017081. Systematic searches found CAT treatment studies reporting treatment refusal and dropout rates. Studies were narratively and quantitatively synthesised in a proportional random-effects meta-analysis and moderator analyses were performed. Secondary analyses compared refusal and dropout rates for CAT versus other psychotherapies via direct comparisons in the original studies and via benchmarking these rates against other acceptability meta-analyses for other psychotherapies. Thirty-four CAT studies were included in the review. The treatment refusal rate was 15.35% (k = 9, 95% CIs 8.78–23.21). The treatment dropout rate was 18.69% (k = 34, 95% CI's 15.02–22.62). CAT generated significantly lower dropout rates relative to treatment comparators in the original studies (OR = 0.67; 95% CI 0.48–0.93). Country and younger age were significant moderators of dropout rates. CAT had a comparable treatment refusal rate and was towards the lower end of the dropout range when benchmarked against other psychotherapies. CAT as a brief and integrative psychotherapy for individuals presenting with typically complex psychological disorders appears a relatively acceptable intervention to patients.
Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19
Authors: Daein Choi, Ori Waksman, Aleesha Shaik, Phyu Mar, Qinzhong Chen, Daniel J. Cho, HyoungSup Kim, Robin L. Smith, Sascha N. Goonewardena, Robert S. Rosenson
Journal: Journal of the American College of Cardiology (2022)
Integrating multiplex immunofluorescent and mass spectrometry imaging to map myeloid heterogeneity in its metabolic and cellular context
Authors: Pieter Goossens, Chang Lu, Jianhua Cao, Marion J. Gijbels, Joël M.H. Karel, Erwin Wijnands, Britt S.R. Claes, Gregorio E. Fazzi, Tim F.E. Hendriks, Kristiaan Wouters, Evgueni Smirnov, Marc J.M. van Zandvoort, Benjamin Balluff, Eva Cuypers, Marjo M.P.C. Donners, Ron M.A. Heeren, Erik A.L. Biessen
Journal: Cell Metabolism (2022)

Cells often adopt different phenotypes, dictated by tissue-specific or local signals such as cell-cell and cell-matrix contacts or molecular micro-environment. This holds in extremis for macrophages with their high phenotypic plasticity. Their broad range of functions, some even opposing, reflects their heterogeneity, and a multitude of subsets has been described in different tissues and diseases. Such micro-environmental imprint cannot be adequately studied by single-cell applications, as cells are detached from their context, while histology-based assessment lacks the phenotypic depth due to limitations in marker combination. Here, we present a novel, integrative approach in which 15-color multispectral imaging allows comprehensive cell classification based on multi-marker expression patterns, followed by downstream analysis pipelines to link their phenotypes to contextual, micro-environmental cues, such as their cellular ("community") and metabolic ("local lipidome") niches in complex tissue. The power of this approach is illustrated for myeloid subsets and associated lipid signatures in murine atherosclerotic plaque.
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Authors: Yu Gao, Curtis Cai, David Wullimann, Julia Niessl, Olga Rivera-Ballesteros, Puran Chen, Joshua Lange, Angelica Cuapio, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Jan Vesterbacka, Mira Akber, Andre Perez-Potti, Takuya Sekine, Thomas R. Müller, Caroline Boulouis, Tobias Kammann, Tiphaine Parrot, Jagadeeswara Rao Muvva, Michal Sobkowiak, Katie Healy, Gordana Bogdanovic, Sandra Muschiol, Gunnar Söderdahl, Anders Österborg, Fredrika Hellgren, Alba Grifoni, Daniela Weiskopf, Alessandro Sette, Karin Loré, Margaret Sällberg Chen, Per Ljungman, Johan K. Sandberg, C.I. Edvard Smith, Peter Bergman, Hans-Gustaf Ljunggren, Soo Aleman, Marcus Buggert
Journal: Immunity (2022)

Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2 mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells post-mRNA vaccination in healthy individuals and patients with various forms of immunodeficiencies. Impaired vaccine-induced cell-mediated immunity was observed in many immunocompromised patients, particularly in solid-organ transplant and chronic lymphocytic leukemia patients. Notably, individuals with an inherited lack of mature B cells, i.e., X-linked agammaglobulinemia (XLA) displayed highly functional spike-specific T cell responses. Single-cell RNA-sequencing further revealed that mRNA vaccination induced a broad functional spectrum of spike-specific CD4+ and CD8+ T cells in healthy individuals and patients with XLA. These responses were founded on polyclonal repertoires of CD4+ T cells and robust expansions of oligoclonal effector-memory CD45RA+ CD8+ T cells with stem-like characteristics. Collectively, our data provide the functional continuum of SARS-CoV-2-specific T cell responses post-mRNA vaccination, highlighting that cell-mediated immunity is of variable functional quality across immunodeficiency syndromes.
Advancing the prevention and treatment of HIV in children: priorities for research and development
Authors: Martina Penazzato, Claire L Townsend, Nadia A Sam-Agudu, Theodore D Ruel, Moherndran Archary, Adrie Bekker, Tim R Cressey, Angela Colbers, Nandita Sugandhi, Pablo Rojo, Natella Rakhmanina, Melynda Watkins, Lisa Frigati, Irene Mukui, Asma Hafiz, Marissa Vicari, Edmund V Capparelli, Elaine J Abrams, Elaine Abrams, Moherndran Archary, Adrie Bekker, Edmund Capparelli, Angela Colbers, Tim Cressey, Lisa Frigati, Asma Hafiz, Irene Mukui, Martina Penazzato, Natella Rakhmanina, Pablo Rojo, Theodore Ruel, Nadia Sam-Agudu, Nandita Sugandhi, Claire Townsend, Marissa Vicari, Melynda Watkins
Journal: The Lancet HIV (2022)
Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
Authors: Hannah S.J. Choi, Grishma Hirode, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace L.H. Wong, Sylvia M. Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Milan J. Sonneveld, Henry L.Y. Chan, Xavier Forns, George V. Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun Hsu, Jia-Horng Kao, Markus Cornberg, Bettina E. Hansen, Wen-Juei Jeng, Harry L.A. Janssen
Journal: Clinical Gastroenterology and Hepatology (2022)

Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy.This study included 1402 virally suppressed CHB patients who stopped either ETV (n = 981) or TDF (n = 421) therapy between 2001 and 2020 from 13 participating centers across North America, Europe, and Asia. All patients were hepatitis B e antigen-negative at treatment discontinuation. Inverse probability of treatment weighting was used to balance the treatment groups. Outcomes were analyzed using survival methods.During a median off-treatment follow-up of 18 months, HBsAg loss occurred in 96 (6.8%) patients overall. Compared with ETV, TDF was associated with a higher rate of HBsAg loss (P = .03); however, the association was no longer significant after statistical adjustment (P = .61). Virological relapse occurred earlier among TDF-treated patients (P < .01); nonetheless, rates became comparable after the first year off therapy (P = .49). TDF was significantly associated with a higher clinical relapse rate than ETV throughout follow-up (P < .01). The development of a virological or clinical relapse did not affect the rate of HBsAg loss. Retreatment rates were not significantly different between the treatment groups.TDF and ETV have differential relapse patterns but are associated with similar rates of HBsAg loss and retreatment following discontinuation. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.
How to Treat Patients With First-Diagnosed Atrial Fibrillation
Authors: Emma Svennberg
Journal: Journal of the American College of Cardiology (2022)

Adults who have been infected with SARS-CoV-2 can develop a multisystem inflammatory syndrome (MIS-A), including fulminant myocarditis. Yet, several patients fail to meet MIS-A criteria, suggesting the existence of distinct phenotypes in fulminant COVID-19–related myocarditis.This study sought to compare the characteristics and clinical outcome between patients with fulminant COVID-19–related myocarditis fulfilling MIS-A criteria (MIS-A+) or not (MIS-A−).A monocentric retrospective analysis of consecutive fulminant COVID-19–related myocarditis in a 26-bed intensive care unit (ICU).Between March 2020 and June 2021, 38 patients required ICU admission (male 66%; mean age 32 ± 15 years) for suspected fulminant COVID-19–related myocarditis. In-ICU treatment for organ failure included dobutamine 79%, norepinephrine 60%, mechanical ventilation 50%, venoarterial extracorporeal membrane oxygenation 42%, and renal replacement therapy 29%. In-hospital mortality was 13%. Twenty-five patients (66%) met the MIS-A criteria. MIS-A− patients compared with MIS-A+ patients were characterized by a shorter delay between COVID-19 symptoms onset and myocarditis, a lower left ventricular ejection fraction, and a higher rate of in-ICU organ failure, and were more likely to require mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (92% vs 16%; P < 0.0001). In-hospital mortality was higher in MIS-A− patients (31% vs 4%). MIS-A+ had higher circulating levels of interleukin (IL)-22, IL-17, and tumor necrosis factor-α (TNF-α), whereas MIS-A− had higher interferon-α2 (IFN-α2) and IL-8 levels. RNA polymerase III autoantibodies were present in 7 of 13 MIS-A− patients (54%) but in none of the MIS-A+ patients.MIS-A+ and MIS-A− fulminant COVID-19–related myocarditis patients have 2 distinct phenotypes with different clinical presentations, prognosis, and immunological profiles. Differentiating these 2 phenotypes is relevant for patients' management and further understanding of their pathophysiology.
Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults
Authors: Petra Barhoum, Marc Pineton de Chambrun, Karim Dorgham, Mathieu Kerneis, Sonia Burrel, Paul Quentric, Christophe Parizot, Juliette Chommeloux, Nicolas Bréchot, Quentin Moyon, Guillaume Lebreton, Samia Boussouar, Matthieu Schmidt, Hans Yssel, Lucie Lefevre, Makoto Miyara, Jean-Luc Charuel, Stéphane Marot, Anne-Geneviève Marcelin, Charles-Edouard Luyt, Pascal Leprince, Zahir Amoura, Gilles Montalescot, Alban Redheuil, Alain Combes, Guy Gorochov, Guillaume Hékimian
Journal: Journal of the American College of Cardiology (2022)
Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity
Authors: Nimesh A. Patel, Luis A. Acaba-Berrocal, Sandra Hoyek, Kenneth C. Fan, Maria Ana Martinez-Castellanos, Caroline R. Baumal, C. Armitage Harper, Audina M. Berrocal, Wu Wei-Chi, Rand Spencer, Shunji Kusaka, Polly Quiram, Jose Asilis, Michael P. Blair, Swati Agarwal, Anna Ells, Cagri G. Besirli, Irena Tsui, Thomas C. Lee, Aaron Nagiel, Andrés Kychenthal, Jessica Kovarik, Anton Orlin, Janet Alexander, Vaidehi S. Dedania, Sengul Ozdek, Michel J. Shami, Cornelius Regan, Shilpa Desai, Moran Roni Levin, Deborah Y. Chong, Mrinali Gupta, Adam Pflugrath, Ashkan Abbey, Christopher G. Fuller, Lori E. Coors, Nicolas Yannuzzi, Catherine Negron, Hasenin Al-khersan, Paul Runge, Huseyin Baran Ozdemir, Tugce Kucukbalci, Chiharu Iwahashi, Mark Solinski, David Sutter, Jonathan Sears, Christine Sonnie, David Portney, Jake Duker, Tamara Lenis, Andreas Di-Luciano, Pablo Chamartin, Nikisha Kothari, Grecia Yael Ortiz-Ramirez, Gabriela Patricia Amadeo Oreggioni, Ameay V. Naravane, Peter J. Belin, Nahomy Ledesma Vicioso, Demetrios Vavvas, M. Elizabeth Hartnett, Robinson V.P. Chan, Eric Nudleman, Darius M. Moshfeghi, Atchara Amphornphruet, Michael Chiang, Michael J. Shapiro
Journal: Ophthalmology (2022)
The effects of 35% trichloroacetic acid-Croton oil and 35% glycolic acid-Croton oil compared to 35% phenol-Croton oil Hetter’s very heavy formula for deep chemical peel
Authors: Bruna Mikulis Lemes, Aline da Silva Justo, Erica Miyake Lin, Anna Claudia M.O. Capote, Anny K.L. Neves, Isadora Machinski, Airton V. Pereira, Adriana Yuriko Koga, Leandro C. Lipinski, Flavio Luis Beltrame, Helio A. Miot, Carlos Gustavo Wambier
Journal: Journal of the American Academy of Dermatology (2022)
Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy
Authors: Andreas Goette, Katrin Borof, Günter Breithardt, A. John Camm, Harry J.G.M. Crijns, Karl-Heinz Kuck, Karl Wegscheider, Paulus Kirchhof
Journal: Journal of the American College of Cardiology (2022)

Whether atrial fibrillation (AF) pattern or timing of AF therapy modifies the effectiveness of early rhythm control (ERC) is not known.This study sought to compare clinical characteristics and outcomes in patients presenting with different AF patterns on ERC vs usual care.The effects of ERC were compared in first-diagnosed AF (FDAF), paroxysmal AF (paroxAF), and persistent AF (persAF) in this prespecified analysis of the EAST-AFNET 4 (Early treatment of atrial fibrillation for stroke prevention) trial. Associations between AF pattern and primary outcomes (first primary outcome: cardiovascular death, stroke, and hospitalization for heart failure and acute coronary syndrome; second primary outcome: nights spent in hospital per year) were compared over a mean follow-up of 5.1 years. Changes in health-related quality of life were assessed by the EQ-5D.FDAF patients (n = 1,048, enrolled 7 days after diagnosing AF) were slightly older (71 years of age, 48.0% female) than patients with paroxAF (n = 994, 70 years of age, 50.0% female) and persAF (n = 743, 70 years of age, 38.0% female). ERC reduced the primary outcome in all 3 AF patterns. Hospitalizations for acute coronary syndrome were highest in FDAF (incidence rate ratio [IRR]: 1.50; 95% CI: 0.83-2.69; P for interaction = 0.032) compared with paroxAF (IRR: 0.64; 95% CI: 0.32-1.25) and persAF (IRR: 0.50; 95% CI: 0.25-1.00). FDAF patients spent more nights in hospital (IRR: 1.38; 95% CI: 1.12-1.70; P for interaction = 0.004) than paroxAF (IRR: 0.84; 95% CI: 0.67-1.03), and persAF (IRR: 1.02; 95% CI: 0.80-1.30) patients. ERC improved health-related quality of life (EQ-5D score) in patients with paroxAF and persAF but not in patients with FDAF (P = 0.019).ERC reduces the first primary composite outcome in all AF patterns. Patients with FDAF are at high risk for hospitalization and acute coronary syndrome, particularly on ERC. (Early treatment of atrial fibrillation for stroke prevention trial; ISRCTN04708680; Early Treatment of Atrial Fibrillation for Stroke Prevention Trial [EAST]; NCT01288352; Early treatment of Atrial fibrillation for Stroke prevention Trial [EAST]; EudraCT2010-021258-20).
Annals On Call - 100th Episode
Authors: Robert M. Centor
Journal: Annals of Internal Medicine (2022)

Web ExclusivesJuly 2022Annals On Call - 100th EpisodeFREERobert M. Centor, MDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A21-0015 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor celebrates the podcast's 100th episode with Drs. Sanjiv Bajaj, Darilyn Moyer, Scott Rosenberg, and Candace Sprott.About Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=A21-0015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics July 2022Volume 175, Issue 7Page: OC1 ePublished: 19 July 2022 Issue Published: July 2022 CopyrightCopyright © 2022 by American College of Physicians. All Rights Reserved.Loading ...
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Authors: Byeong-Keuk Kim, Sung-Jin Hong, Yong-Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum-Kee Hong, Jung Ho Heo, Seung-Woon Rha, Yun-Hyeong Cho, Seung-Jun Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Journal: The Lancet (2022)
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial
Authors: Ajith K Siriwardena, Santhalingam Jegatheeswaran, James M Mason, Ajith K Siriwardena, Santhalingam Jegatheeswaran, James M Mason, Minas Baltatzis, Aali J Sheen, Derek A O'Reilly, Saurabh Jamdar, Rahul Deshpande, Nicola De Liguori Carino, Thomas Satyadas, Ahmed Qamruddin, Katharine Hayden, Michael J Parker, John Butler, Ben McIntyre
Journal: The Lancet. Gastroenterology & hepatology (2022)
Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic TH2 cells and clonal conversion
Authors: Tomohisa Iinuma, Masahiro Kiuchi, Kiyoshi Hirahara, Junya Kurita, Kota Kokubo, Hiroyuki Yagyu, Riyo Yoneda, Tomoyuki Arai, Yuri Sonobe, Masaki Fukuyo, Atsushi Kaneda, Syuji Yonekura, Toshinori Nakayama, Yoshitaka Okamoto, Toyoyuki Hanazawa
Journal: Journal of Allergy and Clinical Immunology (2022)

Allergic rhinitis is a growing problem worldwide. Currently the only treatment that can modify the disease is antigen-specific immunotherapy, but its mechanism of action is not fully understood.We comprehensively investigated the role and changes of antigen-specific T cells before and after sublingual immunotherapy (SLIT) for Japanese cedar pollinosis.We cultured peripheral blood mononuclear cells obtained both before and 1 year after initiating SLIT and used a combination of single-cell RNA sequencing and repertoire sequencing. To investigate biomarkers, we used cells from patients participating a phase 2/3 trial of SLIT tablets for Japanese cedar pollinosis and cells from outpatients with good and poor response.Antigen-stimulated culturing after SLIT led to clonal expansion of TH2 and regulatory T cells, and most of these CD4+ T cells retained their CDR3 regions before and after treatment, indicating antigen-specific clonal responses and differentiation resulting from SLIT. However, SLIT reduced the number of clonal functional TH2 cells but increased the trans-type TH2 cell population that expresses musculin (MSC), TGF-β, and IL-2. Trajectory analysis suggested that SLIT induced clonal differentiation of the trans-type TH2 cells differentiated into regulatory T cells. Using real-time PCR, we found that the MSC levels increased in the active SLIT group and those with good response after 1 year of treatment.The combination of single-cell RNA sequencing and repertoire analysis helped reveal part of the underlying mechanism: SLIT promotes the expression of MSC on pathogenic TH2 cells and suppresses their function. MSC may be a potential biomarker of SLIT for allergic rhinitis.
Cytochrome P450 oxidase 2J inhibition suppresses choroidal neovascularization in mice
Authors: Yan Gong, Yohei Tomita, Matthew L Edin, Anli Ren, Minji Ko, Jay Yang, Edward Bull, Darryl C Zeldin, Ann Hellström, Zhongjie Fu, Lois E H Smith
Journal: Metabolism (2022)
Urban-Rural Trends in Young Stroke-Related Mortality in the United States, 1999-2019
Authors: Robert W. Ariss, Abdul Mannan Khan Minhas, Jacob Lang, P. Kasi Ramanathan, Safi U. Khan, Mahwash Kassi, Haider J. Warraich, Dhaval Kolte, Mohamad Alkhouli, Salik Nazir
Journal: Journal of the American College of Cardiology (2022)
Emergence of blaKPC-33-harboring Hypervirulent ST463 Pseudomonas aeruginosa Causing Fatal Infections in China
Authors: Piaopiao Zhang, Jie Wang, Yue Li, Weixiao Shi, Heng Cai, Qing Yang, Xi Li, Yunsong Yu, Tingting Qu, Yan Jiang
Journal: Journal of Infection (2022)
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis
Authors: Caifang Gao, Yangyang Zhou, Zhejie Chen, Hongyi Li, Yaqin Xiao, Wei Hao, Ying Zhu, Chi Teng Vong, Mohamed A. Farag, Yitao Wang, Shengpeng Wang
Journal: Theranostics (2022)

Rationale: Ulcerative colitis (UC), a typical kind of inflammatory bowel disease (IBD), is an idiopathic chronic intestinal inflammation.Conventional therapeutic strategies mainly focus on the rebalance of pro-inflammation and anti-inflammation cytokines, whereas targeting damaged intestinal barriers, imbalanced intestinal microbiota and dysregulated mucosal immune responses in UC remain a big challenge.The objective of this study was to develop turmeric-derived nanovesicles (TNVs) for alleviation of colitis and explore the underlying mechanisms.Methods: TNVs were isolated and purified through differential centrifugation.The targeted ability was evaluated on the dextran sulfate sodium (DSS)-induced mouse model by IVIS imaging system.The anti-inflammation efficacy was studied in lipopolysaccharide (LPS)-induced macrophages and DSS-induced acute and chronic colitic mouse model.In addition, the influence of TNVs on the intestinal microbiota was investigated via 16S rRNA microbiome sequence and the condition of macrophage polarization after TNVs treatment was analyzed by flow cytometry.Results: TNVs were isolated and characterized as nano-size spheroids.The IVIS imaging experiment indicated that orally administrated TNVs could accumulate in the inflamed colon sites and exhibited superior anti-inflammatory activity both in vitro and in vivo.The 16S rRNA sequencing suggested the important role of TNVs in the regulation of gut microbiota.Further, TNVs could promote the transformation of M1 phenotype to M2 macrophages and restore the damaged intestinal epithelium barrier to exert the anti-colitis efficacy.Conclusion: Collectively, oral administration of TNVs exhibited excellent anti-inflammatory efficacy through restoring the damaged intestinal barrier, regulating the gut microbiota and reshaping the macrophage phenotype.This study sheds light on the application of natural exosome-like nanovesicles for the treatment of UC.
Evaluation of <sup>18</sup>F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue: Erratum
Authors: François-Xavier Lepelletier, Matthias Vandesquille, Marie-Claude Asselin, Christian Prenant, Andrew C Robinson, David M A Mann, Michael Green, Elizabeth Barnett, Samuel D Banister, Marco Mottinelli, Christophe Mesangeau, Christopher R McCurdy, Inga B Fricke, Andreas H. Jacobs, Michael Kassiou, Hervé Boutin
Journal: Theranostics (2022)

[This corrects the article DOI: 10.7150/thno.47585.].